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HEALTH LAW-VACCINE INJURIES-FEDERAL LAW PRESCRIBES
PROCEDURES FOR ALTERNATIVES TO TORT ACTIONS FOR VACCINE-
RELATED INJURIES. THE NATIONAL CHILDHOOD VACCINE INJURY
COMPENSATION ACT OF 1986. 42 U.S.C. §§ 300aa-1 to -34 (Supp. IV
1986).
During the past two decades this country developed a national
program of childhood immunizations.' This program's goal is to re-
duce the morbidity and mortality that accompanies many of the infec-
tious childhood diseases.2 While this program has been extremely
successful in most respects, the mass immunization of a large percent-
age of our nation's children has also been responsible for a small, but
significant, number of vaccine-related injuries and deaths.'
In the past, those suffering injuries as a result of adverse reac-
tions to vaccines turned to the tort system for relief.4 Plaintiffs often
found this avenue very expensive in terms of both time and money,
and in many instances, they were left without compensation.' In ad-
dition to the inequities suffered by those already injured, this litigation
was responsible for a crisis that continues to threaten the national
immunization program. Litigation expenses and increasing liability
insurance premiums drove some manufacturers from the marketplace
and forced those remaining to increase the price of vaccines
substantially.6
In response to this crisis, Congress amended the Public Health
Service Act by enacting the National Childhood Vaccine Injury Com-
pensation Act of 1986 (Act).7 Congress passed the Act without fund-
ing provisions in the closing days of the 99th Congress. An
amendment to the Omnibus Budget Reconciliation Act provided ini-
1. STAFF OF HOUSE SUBCOMM. ON HEALTH AND THE ENVIRONMENT OF THE HOUSE
COMM. ON ENERGY AND COMMERCE, 99TH CONG., 2D SESS., REPORT ON CHILDHOOD IM-
MUNIZATIONS 43 (Comm. Print 1986) [hereinafter Comm. Print].
2. Id.
3. HOUSE COMMITTEE ON ENERGY AND COMMERCE NATIONAL CHILDHOOD VAC-
CINE INJURY ACT OF 1986, H.R. REP. No. 99-908, 99th Cong., 2d Sess. 4, reprinted in 1986
U.S. CODE CONG. & ADMIN. NEWS 6344, 6345 [hereinafter Legislative History].
4. Id.
5. Id. at 6, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6347.
6. Smith, National Childhood Vaccine Injury Compensation Act, 82 PEDIATRICS 264, 266
(1988).
7. 42 U.S.C. § 300aa (Supp. IV 1986). The Act provides compensation for injuries re-
lated to the administration of vaccines against communicable childhood diseases, specifically,
measles, mumps, rubella, diphtheria, pertussis, polio, and tetanus. Id. § 300aa-14.
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tial funding for the programs established in the Act.' A trust fund
established by the Act9 and funded by excise taxes imposed on vaccine
sales' 0 will provide additional revenue.
The Act creates two new programs in response to concerns about
a safe and sufficient supply of vaccines and the inequities found in tort
litigation against manufacturers. The first of these programs (the Na-
tional Vaccine Program) will assure the research and development of
better and safer vaccines, I while the second (the National Childhood
Vaccine Injury Compensation Program) provides a system of "no
fault" compensation for persons suffering from vaccine-related inju-
ries. 12 A third section of the Act sets forth specific rules for recording
and reporting information pertaining to the administration of vac-
cines and any adverse reactions that may occur.13
The purpose of the National Vaccine Program is to coordinate
and direct research on means to induce immunity and prevent adverse
reactions.' 4 This Program will oversee testing, licensing, production,
and distribution of vaccines by various governmental and non-govern-
mental agencies including the Centers for Disease Control (CDC) and
the National Institutes of Health (NIH). 5
The aim of the National Childhood Vaccine Injury Compensa-
tion Program (Compensation Program) is to provide a system for
compensating those persons suffering vaccine-related injuries in a fair
and expeditious manner, and alleviating the expense and long delays
often encountered in the courts.' 6 This goal is facilitated by the crea-
tion of a mandatory "no fault" system of compensation that discour-
ages the use of the court system by requiring the vaccine-injured
person to complete the compensation proceedings before suing. 7 The
Compensation Program does not prohibit the use of the courts for
8. 26 U.S.C.A. § 4131 (West 1989).
9. 26 U.S.C.A. § 9510 (West Supp. 1989).
10. Id. § 9510(b). The taxes placed on the various vaccines are as follows: Diphtheria-
Pertussis Tetanus (DPT), $4.65/dose, Measles-Mumps-Rubella (MMR), $4.44/dose, Oral Po-
lio Vaccine (OPV), $0.29/dose, and Tetanus-Diphtheria (TD), $0.06/dose. Id. § 4131(b)(1).
11. 42 U.S.C. § 300aa-1 (Supp. IV 1986).
12. Id. § 300aa-10.
13. Id. § 300aa-25.
14. Legislative History, supra note 3, at 9, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6350. By conducting research to enhance knowledge about diseases, pathogens, and
host responses, the development of safer vaccines should be possible.
15. Id. The Food and Drug Administration (FDA), the Department of Defense, and the
Agency for International Development are also conducting research in the area of vaccine
development.




compensation, but is intended to make litigation a last resort. As an
added deterrent to litigation, the Act limits the theories under which a
tort claim may be filed. 8 National Childhood Vaccine Injury Com-
pensation Act of 1986, 42 U.S.C. §§ 300aa-1 to -34 (Supp. IV 1986).
There can be little doubt that our nation's initiatives in providing
immunization programs for its children have been beneficial both so-
cially and economically. Some of the common childhood diseases are
quite contagious' 9 and, in the past, these diseases have caused serious
epidemics. Diseases that most of today's children will never acquire,
killed or maimed many children only a few generations ago.2 °
Since Edward Jenner's pioneering work with smallpox in 1796,
science has developed vaccines to prevent a wide variety of communi-
cable diseases. 21 The federal government recognized the benefits of
vaccine use and assumed a leadership role in establishing a national
immunization program.22 With federal support, state and local public
health services in all fifty states established mandatory immunization
programs for school children.23
The social benefits of the use of vaccines are most striking when
viewed in terms of the number of lives saved each year. One report
states that the "[u]se of vaccines against illness has prevented
thousands of deaths each year ... and has substantially reduced the
morbidity resulting from disease."24 For example, in 1941 measles
caused 2,250 deaths in the United States, but in 1983, measles only
caused two deaths. 25 The use of vaccines produced similar reductions
18. Id. at 25-26, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6366-67. This
note will discuss the procedural aspects of the compensation program for the practicing
attorney.
19. R. EDMOND, J. BRADLEY & N. GALBRAITH, INFECTION (1982).
20. For example, in the United States, diphtheria caused more than 15,000 deaths in 1921,
measles caused 2,250 deaths in 1941, pertussis caused 2,500 deaths in 1942, and polio caused
more than 3,000 deaths in 1952. Interview with Dennis A. Berry, Communicable Disease
Section, Arkansas Department of Health (Feb. 9, 1989).
21. G. MANDELL, R. DOUGLAS & J. BENNETT, PRINCIPLES AND PRACTICE OF INFEC-
TIOUS DISEASES 1690 (2d ed. 1979).
22. Comm. Print, supra note 1, at 43 & n.155. Some early public health legislation placed
the supervision of maritime quarantine under the Secretary of the Treasury (1799), sought to
prevent the introduction of communicable diseases into the United States (1878), and gave the
Public Health Service responsibility for foreign and interstate quarantine (1893). Id.
23. Id. at 47. In order to ensure the immunization of all children, such programs require
proof of vaccination as a condition to school entry and attendance. By the 1981-82 school
year, 97 percent of the students entering U.S. schools had been immunized against measles and
rubella, 96 percent against polio, diphtheria, tetanus, and pertussis, and 95 percent against
mumps. Id.




in the mortality of other diseases and was responsible for the total
eradication of smallpox.26 In addition to the lives saved, there has
also been a realization of economic benefits. It is estimated that im-
munizations saved "[b]illions of medical and health-related dollars."27
Unfortunately, however, the immunization program has not been
without its own expense which led to the creation of the Compensa-
tion Program.
Although the vaccines produced in the United States today are
subjected to a wide range of clinical trials to assure their safety and
efficacy, these trials are sometimes not sufficient to detect rarely oc-
curring adverse reactions.28 Consequently, when a vaccine is placed
on the market and used in a mass immunization program, previously
undetected adverse reactions may come to light.29 These adverse re-
actions range from mild, local discomfort at the injection site, to more
severe reactions such as febrile convulsions and death.30 In addition
to the adverse reactions that may be observed in the individual receiv-
ing the vaccine, certain vaccines (such as the Sabin oral polio vaccine)
are capable of causing disease in susceptible persons who come in con-
tact with the immunized individual.3'
Adverse reactions are rare and usually unforeseeable. Conse-
quently, physicians and public health officials agree that while immu-
nization is not risk-free, the risks are outweighed by the benefits.32
This risk-benefit analysis provides little consolation for those few indi-
viduals who suffer vaccine-related injuries-injuries for which they
are not at fault and resulting from their efforts to comply with
26. Id.
27. Legislative History, supra note 3, at 4, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6345.
28. Adverse Events Following Immunization, 34 MORBIDITY & MORTALITY WEEKLY
REP. 43 (1985).
29. Id.
30. Id. Febrile convulsions are those that occur in patients (usually pediatric) with high
fevers. STEDMAN'S MEDICAL DICTIONARY (Illustrated) 318 (24th ed. 1982).
31. J. CONTE & S. BARRIERE, MANUAL OF ANTIBIOTICS AND INFECTIOUS DISEASES 248
(6th ed. 1988). Persons who receive vaccines made with live viruses (for example polio or
measles) may shed the virus in some body excretions, particularly urine, for several weeks. If
hygiene is poor, the virus may be transmitted to a susceptible person.
32. Legislative History, supra note 3, at 6, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6347. See also OFFICE OF TECHNOLOGY ASSESSMENT REPORT: COMPENSATION
FOR VACCINE-RELATED INJURIES 19 (1980) [hereinafter OTA Report]. One benefit of immu-
nization programs is a phenomenon known as "herd immunity" wherein the immunization of
a large percent of a population against a specific disease protects those persons not immunized




mandatory immunization requirements.13 In their search for com-
pensation, individuals with vaccine-related injuries began turning to
the tort system with suits against the manufacturers.34
The blame for vaccine-related injuries can scarcely be laid at the
feet of the victim, but it is equally unfair to say that the blame lies
with the manufacturer when the vaccine was produced in compliance
with government regulations. 3 In an effort to provide some measure
of relief for these injuries, the courts began to fashion remedies within
the tort system.3 6 Unfortunately, the use of the tort system created
inequities because "the opportunities for redress and restitution are
limited, time-consuming, expensive, and often unanswered. ' '37 While
court-ordered awards provided relief for some individuals with vac-
cine injuries, others with similar injuries have been left with nothing."
Because vaccines are generally considered "unavoidably unsafe
products, 3 a9 it is difficult for a plaintiff to prevail under traditional
33. Legislative History, supra note 3, at 6, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6347.
34. Id. at 4, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6345. See, e.g.,
Givens v. Lederle, 556 F.2d 1341 (5th Cir. 1977); Reyes v. Wyeth Laboratories, 498 F.2d 1264
(5th Cir. 1974); Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968).
35. Krugman, Immunization "dyspractice.'" The need for "no fault" insurance, 56 PEDI-
ATRICS 159 (1975).
36. See, e.g., Givens v. Lederle, 556 F.2d 1341 (5th Cir. 1977); Reyes v. Wyeth Laborato-
ries, 498 F.2d 1264 (5th Cir. 1974); Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir.
1968).
37. Legislative History, supra note 3, at 6-7, reprinted in 1986 U.S. CODE CONG. & AD-
MIN. NEWS at 6347-48.
38. Id. at 6, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6347. See, e.g.,
Schindler v. Lederle Laboratories, 725 F.2d 1036 (6th Cir. 1983); Kearl v. Lederle Laborato-
ries, 172 Cal. App. 3d 812, 218 Cal. Rptr. 453 (1985); Dunn v. Lederle Laboratories, 121
Mich. App. 73, 328 N.W.2d 576 (1983).
39. RESTATEMENT (SECOND) OF TORTS § 402A comment k. Comment k reads in part:
Unavoidably unsafe products. There are some products which, in the present state of
human knowledge, are quite incapable of being made safe for their intended and
ordinary use. These are especially common in the field of drugs. An outstanding
example is the vaccine for Pasteur treatment of rabies, which not uncommonly leads
to very serious and damaging consequences when it is injected. Since the disease
itself invariably leads to a dreadful death, both the marketing and the use of the
vaccine are fully justified, notwithstanding the unavoidable high degree of risk which
they involve. Such a product, properly prepared, and accompanied by proper direc-
tions and warning, is not defective, nor is it unreasonably dangerous. The same is
true of many other drugs, vaccines, and the like, many of which for this very reason
cannot legally be sold except to physicians, or under the prescription of a physi-
cian. . . . The seller of such products, again with the qualification that they are
properly prepared and marketed, and proper warning is given, where the situation
calls for it, is not to be held to strict liability for unfortunate consequences attending
their use, merely because he has undertaken to supply the public with an apparently
useful and desirable product, attended with a known but apparently reasonable risk.
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strict liability theories. In Davis v. Wyeth Laboratories, Inc.,' the
court found that the manufacturer's failure to warn recipients of po-
tential adverse reaction was a basis for liability.4" In Davis, a thirty-
nine-year-old man contracted polio after being immunized with the
Type III Sabin oral polio vaccine.42 Although Wyeth took the pre-
caution of adding a package insert warning of potential adverse effects
in adults receiving the oral polio vaccine, the manufacturer made no
other efforts to warn the public.43 Mr. Davis received the vaccine at a
mass immunization clinic from a pharmacist who failed to read the
insert." The court found that Wyeth had not taken proper precau-
tions to assure that vaccine recipients were warned of the risks in-
volved thus depriving them of the ability to make an informed
decision about immunization.4" The manufacturer's failure to di-
rectly warn vaccine recipients rendered the vaccine "unreasonably
dangerous."'46
Since Davis, courts have found manufacturers liable based on
"failure to warn" in a variety of fact situations. Some of these cases
expanded the manufacturer's duty to the consumer.47 The Ninth Cir-
cuit48 held in Toner v. Lederle Laboratories, Div. of American Cyana-
mid Co., that while the manufacturer was not strictly liable for the
plaintiff's paralysis, Lederle's failure to develop and market a safer
vaccine constituted negligence. This holding was based on a finding
that an alternative vaccine was available and Lederle had failed to
produce evidence showing that the FDA would not have approved
Id. (emphasis in original).
40. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968).
41. Id. at 130.
42. Id. at 122.
43. Id. at 125.
44. Id.
45. Id. at 130.
46. Id. The dissent in this case was based on the fact that the local Medical Society was in
charge of the mass immunization program and was aware of the Surgeon General's report.
The Medical Society decided to proceed with the program in spite of the warnings. Conse-
quently it could not be held that, as a matter of law, the manufacturer had breached its duty to
warn. Id. at 131-32 (Hamlin, J., dissenting).
47. See Reyes v. Wyeth Laboratories, 498 F.2d 1264 (5th Cir. 1974) (failure to provide
warning of risk or to provide medical judgment that treatment was necessary). See also Givens
v. Lederle, 556 F.2d 1341 (5th Cir. 1977) (duty to take action to provide information to actual
consumer). For a review of vaccine injury cases in favor of plaintiffs, see Comment, Vaccine-
Related Injuries: Alternatives to the Tort Compensation System, 30 ST. Louis U.L.J. 919
(1986).
48. Toner v. Lederle Laboratories Div. of American Cyanamid Co., 831 F.2d 180 (9th
Cir. 1987), modifying 828 F.2d 510 (9th Cir. 1987) (infant suffered paralysis after receiving




such a vaccine.4 9  However, in Johnson v. American Cyanamid Co.,5°
the Kansas Supreme Court refused to expand the manufacturer's duty
to warn and found that a manufacturer was not negligent because of
its failure to provide warnings directly to vaccine recipients. In spite
of the manufacturer's success in American Cyanamid, cases such as
those noted above, coupled with increasing insurance costs, had a
profound negative effect on vaccine manufacturers.
A number of factors are responsible for this effect. First, vaccine
sales account for a relatively small portion of a manufacturer's overall
sales because of the limited market for vaccines." Second, the cost of
entry into the market is high, especially when compared to eventual
revenues. 3 Third, "recent court cases have increased the risk of par-
ticipating in the vaccine market."54 Finally, liability insurance premi-
ums for vaccine manufacturers increased while policy limits
decreased. 5 The sum of these factors forced manufacturers to recon-
sider participation in the vaccine market and resulted in temporary
shortages in vaccine supplies.5 6
Although the medical community stands in favor of this coun-
try's immunization programs, it also recognizes the problems and po-
tential risks inherent in such programs. As early as 1975, an article
published in Pediatrics5 7 called for legislation to provide compensa-
tion for those suffering vaccine injuries. In his commentary, Dr.
Richard Krugman of the University of Colorado noted the compensa-
tion legislation enacted in Europe and Asia.58 He went on to say that
because society as a whole benefits from mandatory immunization
laws, "[s]ociety-not the manufacturer, the physician, or the pa-
49. Toner v. Lederle Laboratories, Div. of American Cyanamid Co., 828 F.2d 510, 514
(9th Cir. 1987).
50. 243 Kan. 291, 758 P.2d 206 (1988).
51. Legislative History, supra note 3, at 6, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6347. See also Plummer v. Lederle Laboratories, No. 81-2037 (S.D.N.Y. Oct. 1,
1984).




56. Id. See also Diphtheria-Tetanus-Pertussis Vaccine Shortage-United States, 33 MOR-
BIDITY & MORTALITY WEEKLY REP. 695 (1984). During the second half of 1984, two of the
three manufacturers of DTP vaccine (Wyeth and Connaught) stopped distributing their prod-
uct. A third manufacturer (Lederle) experienced problems with some lots of vaccine which
prevented the release of the vaccine. In December of 1984, the CDC recommended modifica-
tions of DTP dosing schedules until supplies could be replenished. Id.
57. See generally Krugman, supra note 35.
58. Id. at 159-60. The author notes programs in Denmark, Germany and Japan designed
to reimburse victims injured by vaccines administered under mandatory immunization laws.
1988-89]
UALR LAW JOURNAL
tient-should support those who suffer the adverse consequences of
our laws."59
The medical community was not alone in its concern. In 1977
the Department of Health, Education and Welfare began looking at
all aspects of immunization.' While the studies ordered by HEW
focused, in part, on the liability associated with immunizations, no
formal recommendations were made at that time.6' By 1980, how-
ever, the House of Representatives called for a study to "delineate the
specific elements and principles necessary for inclusion in a legislative
proposal for vaccine injury compensation."' 62 During the next three
years, the calls for legislation increased with groups such as the
American Academy of Pediatrics and parents' organizations such as
Dissatisfied Parents Together (DPT) speaking out in favor of a com-
61pensation program.
In 1983 Senator Paula Hawkins introduced a proposal for com-
pensation legislation to the Senate,' 4 and in 1984, Congressman Wax-
man brought similar legislation before the House.65 Although the
provisions of these proposals were quite similar to those of the present
Act, the earlier proposals made use of the compensation system op-
tional rather than mandatory.66 The 98th Congress adjourned with-
out enacting a compensation program.67 It is of note that the most
serious vaccine shortages68 occurred while Congress deliberated about
the fate of the compensation legislation.69
The proponents of compensation legislation again sought support
for their proposals when the 99th Congress convened.7 ° In a Com-
mittee hearing on proposed compensation legislation, Senator Dale
Bumpers pointed out that while such a compensation program would
be costly, "the cost of vaccines and, therefore, the cost of the immuni-
zation program itself will continue to increase alarmingly, perhaps en-
59. Id. at 159.
60. Smith, supra note 6, at 265.
61. Id.
62. Id.
63. Id. at 266.
64. S. 2117, 98th Cong., 1st Sess. (1983).
65. H.R. 5810, 98th Cong., 2d Sess. 130 CONG. REC. 15,484 (1984).
66. National Childhood Vaccine Injury Compensation Act. Hearings on S. 2117Before the
Comm. on Labor and Human Resources, 98th Cong., 2d Sess. 187 (1984) (statement of Alan
R. Nelson, M.D., American Medical Association, Board of Trustees).
67. Smith, supra note 6, at 267.
68. Id.
69. Id.
70. Id. Senators Hawkins, Hatch, Bumpers, and Matsunaga, and Congressman Waxman
were responsible for re-introducing vaccine compensation proposals to the Congress. Id.
[Vol. 11:749756
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dangering the program and our children's health if we don't address
the problem of vaccine-related injuries."'" His remarks mirrored the
concerns expressed by Mrs. Bumpers in a house subcommittee hear-
ing on the Federal Childhood Immunization Program,7 2 and pointed
out the relationship between the two programs.73 Senator Bumpers
noted the recent vaccine availability crisis and further noted that he
was committed to seeing that families in this country never again face
the devastation of childhood diseases. 74 This commitment he said,
''means insisting on adequate funding for the vaccine program itself
and also fair compensation to children who, through no one's fault,
develop the statistically inevitable vaccine-related injuries.
' 75
As the 99th Congress drew to a close, it became apparent to the
Act's proponents that certain aspects of the legislation made passage
unlikely.76 The proposed legislation contained provisions for a surtax
on vaccines to provide revenue for the compensation program. 77 Con-
gressional rules78 require Ways and Means Committee hearings on
such provisions. 79  Late in 1986 it became obvious that a hearing
would be impossible before the end of the session.8 0 Supporters of the
legislation agreed to the removal of the funding provisions to enable
passage of the Act as part of an omnibus health package.8 1 This pack-
age was the last item acted upon before Congress adjourned in 1986.82
The language of the Act "made the compensation program and
accompanying tort reforms contingent on the enactment of a tax to
provide funding for the compensation."83 In an effort to protect the
71. National Childhood Vaccine Injury Compensation Act of 1985.: Hearings on S.827
Before the Comm. on Labor and Human Resources, 99th Cong., 1st Sess. 7 (1985) (statement
of Sen. Dale Bumpers) (hereinafter Senate Hearing).
72. Federal Childhood Immunization Program: Hearings Before the Subcomm. on Health
and the Environment of the Comm. on Energy and Commerce, 99th Cong., 2d Sess. 2 (1986)
(statement of Betty Bumpers, Charleston, Arkansas).
73. See Senate Hearing, supra note 71, at 9.
74. Id.
75. Id.
76. Smith, supra note 6, at 267. At this point, the various proponents of the Act, although
often at odds on specific provisions of the legislation, realized that their differences must be set
aside and compromises made to allow passage of the Act. Telephone interview with Elizabeth
Goss, Legislative Assistant for Sen. Dale Bumpers (Feb. 9, 1989).
77. Smith, supra note 6, at 267.
78. STAFF OF HOUSE COMM. ON WAYS AND MEANS, 99TH CONG., IST SESS. MANUAL
OF RULES OF THE COMMITTEE ON WAYS AND MEANS FOR THE NINETY-NINTH CONGRESS
15 (Comm. Print 1985).




83. HOUSE SUBCOMM. ON HEALTH AND THE ENVIRONMENT, OMNIBUS BUDGET REC-
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needed provisions from veto, the Act's supporters introduced the
funding provisions to the 100th Congress as an amendment to the
Omnibus Budget Reconciliation Act of 1987.84 In addition to funding
provisions, this legislation also contained other amendments to the
Act.85 These changes dealt primarily with payment provisions and
were made in an effort to assure the success of the program.86 An-
other significant amendment protected vaccine administrators (pedia-
tricians, immunization clinics, etc.) in much the same manner as
manufacturers.87 In December of 1987, President Reagan signed the
Budget Reconciliation Act into law, and the National Childhood Vac-
cine Injury Compensation Act of 198688 became a reality.89
The purpose of the Act is to provide an expedient and fair system
of compensation for those persons suffering adverse reactions as a re-
sult of the administration of vaccines. 90 The Act sets forth a Vaccine
Injury Table which provides a list of the vaccines covered by the Act
and the injuries for which compensation may be allowed. 9' Although
this Act does not prohibit a party from seeking compensation through
civil action, it discourages such action by requiring parties to first
complete administrative compensation proceedings before pursuing
those actions.92 The Act also limits the theories upon which a civil
tort action may be filed.93
The program charges attorneys to advise clients of the possibility
of compensation under the program. 94 After the effective date of the
Act,95 most plaintiffs with vaccine-related injuries will be required to
ONCILIATION ACT, H. REP. 391(I), 100th Cong., 1st Sess. 544, reprinted in 1987 U.S. CODE
CONG. & ADMIN. NEWS 2313-64 [hereinafter Budget Act History].
84. Smith, supra note 6, at 267.
85. Budget Act History, supra note 83, at 690, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS at 2313-64.
86. Id.
87. Id. at 699, reprinted in 1987 U.S. CODE CONG. & ADMIN. NEWS at 2313-73.
88. 42 U.S.C. § 300aa-1-34 (Supp. IV 1986).
89. Smith, supra note 6, at 267.
90. Legislative History, supra note 3, at 3, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6344.
91. 42 U.S.C. § 300aa-14 (Supp. IV 1986).
92. Legislative History, supra note 3, at 3, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6344. See also 42 U.S.C. § 300aa-ll (Supp. IV 1986).
93. 42 U.S.C. § 300aa-22 (Supp. IV 1986). See infra text accompanying notes 155-61.
94. 42 U.S.C. § 300aa-10(b) (Supp. IV 1986).
95. Budget Act History, supra note 83, at 696, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS at 2313-70. The original effective date of the compensation and tort reform
provisions established by the Act was based on the date of enactment of an excise tax to fund
the program. This excise tax became effective January 1, 1988. Other sections of the legisla-
tion require that a disability be of at least six months duration before a petition may be filed.
[Vol. 11:749
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complete compensation program proceedings before filing a civil ac-
tion.96 However, depending upon the date of the injury, certain other
plaintiffs may not be eligible for compensation under the program and
may proceed directly to civil actions.97 The class of proper petitioners
includes, "any person who has sustained a vaccine-related injury, the
legal representative of such person if such person is a minor or is dis-
abled, or the legal representative of any person who died as the result
of the administration of a vaccine set forth in the Vaccine Injury Ta-
ble." 98 The Act also allows petitions by persons who contracted polio
as a result of their exposure to another person who received a
vaccine. 99
Although the Act bars petitions by persons who have been
awarded damages in prior civil suits,"' persons who had such actions
dismissed or damages denied are not precluded from filing a peti-
tion.' In addition, persons with civil suits pending on the effective
date of the Act 0 2 have the option of withdrawing such suits and filing
petitions under the Compensation Program. 103 However, if these ac-
tions are not withdrawn, the persons bringing the actions are barred
The effective date of the compensation provision was October 1, 1988, thus allowing a nine
month accumulation of excise taxes before the first compensation claims may be filed. Id.
96. 42 U.S.C. § 300aa-I l(a)(2)(A) (Supp. IV 1986). This section provides:
No person may bring a civil action for damages in an amount greater than $1000 or
in an unspecified amount against a vaccine administrator or manufacturer in a State
or Federal court for damages arising from a vaccine-related injury or death associ-
ated with the administration of a vaccine after the effective date of this subpart, and
no such court may award damages in an amount greater than $1,000 in a civil action
for damages for such vaccine-related injury or death, unless-
(i) a petition has been filed in accordance with § 300aa-16...
(ii) the United States Claims Court has issued a judgment under § 300aa-12 on
such petition, and
(iii) such person elects under § 300aa-2 1(a) to file such an action.
Id.
97. Legislative History, supra note 3, at 22-23, reprinted in 1986 U.S. CODE CONG. &
ADMIN. NEWS at 6363-64.
98. 42 U.S.C. § 300aa-1 l(b)(1)(A) (Supp. IV 1986).
99. Id. § 300aa-1 l(c)(1)(A) (petitions for compensation must demonstrate that the person
who suffered the injury "received a vaccine . ..or, if such person did not receive such a
vaccine, contracted polio, directly or indirectly, from another person who received an oral
polio vaccine.").
100. Id. § 300aa-11(a)(7).
101. Id. § 300aa- l(a)(4) (this section pertains to civil actions filed before the effective date
of the legislation).
102. Budget Act History, supra note 83, at 696, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS at 2313-70 (October 1, 1988). See supra note 95.
103. 42 U.S.C. § 300aa-I I(a)(5)(A) (Supp. IV 1986). Such civil actions must be withdrawn
within two years of the effective date of the legislation or before judgment, whichever is first.
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from filing a petition for compensation."0 4
The petition for compensation must contain specific materials set
forth in the Act.105 Put simply, the affidavit must show the elements
required in a civil negligence action with the notable exception that
there need be no allegation of negligence. The affidavit must include
evidence that the petitioner:
[R]eceived a vaccine listed in the Table or contracted polio
from a recipient or [sic] oral polio vaccine;
met certain citizenship or location restrictions;
sustained or had significantly aggravated an injury listed in
the Table;
sustained or had aggravated the injury within the time periods
specified in the Table;
suffered residual effects for more than [six months] or died or
incurred unreimbursable expenses of greater than $1,000; and
has not previously collected an award or settlement for the
injury.
106
In addition to the affidavit, the petition must include the petitioner's
medical records relating to the injury or identification of unavailable
records'017 and documentation of any evaluations, assessments or
other records that reasonably relate to the determination of the
amount of compensation. 0
Once completed, the petition must be filed in the United States
Claims Court.0 9 The Secretary of the Department of Health and
Human Services (HHS) has been designated as the Administrator of
the program, and service upon the Secretary, as respondent, initiates
the proceedings. 10
The United States Claims Court has jurisdiction over entitlement
proceedings and the issuance and enforcement of any orders necessary
to assure payment of compensation awards."' The court will appoint
a special master to serve as an adjunct to the court." 2 In this capac-
ity, the special master has the power to request evidence, information,
104. Id. § 300aa-l l(a)(5)(B).
105. Id. § 300aa-ll(c).
106. Legislative History, supra note 3, at 15, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6356.
107. 42 U.S.C. § 300aa-11(c)(2) (Supp. IV 1986).
108. Id. § 300aa-ll(c)(3).
109. Id. § 300aa-lI(a)(1).
110. Id. §§ 300aa-10(a), -11(a), -12(b).
111. Id. § 300aa-12(a).
112. Id. § 300aa-12(c)(1).
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and testimony relating to entitlement, and to conduct any necessary
hearings."I3 The findings of the special master are then submitted to
the court for further action.'
The court reviews the findings of the special master on its own
motion or in response to objections from the petitioner or respon-
dent. 1 15 If there are no objections from either party, the court may
choose not to review the findings and may render a judgment based
on an adoption of the findings."I6
The petitioner must prove by a preponderance of the evidence
that the person who suffered the injury "sustained, or had signifi-
cantly aggravated, any illness, disability, injury, or condition . . . or
died" as a result of the administration of a vaccine set forth in the
Vaccine Injury Table."I7 The court must also find, by a preponder-
ance of the evidence, that the injuries described in the petition were
not caused by "factors unrelated to the administration of the vaccine
described in the petition.' II The court will base its decision to award
compensation on any relevant medical and scientific evidence pro-
duced, including medical conclusions, judgments or reports "regard-
ing the nature, causation, and aggravation of the petitioner's illness,
disability, injury, condition, or death.""' ' Decisions of the court will
be announced as soon as practicable, but in any event, such decisions
must be rendered within one year of the filing of the petition. 2 ° If
neither party appeals, the decisions of the claims court will be final.' 2
The Act establishes separate rules for compensation awards
based on the date of the injury in relation to the effective date of the
Compensation Program.'22 Awards for injuries sustained from vac-
113. Id. § 300aa-12(c)(2)(A-D).
114. Id. § 300aa-12(c)(2)(E). This section also provides:
Information submitted to a special master in a proceeding on a petition may not be
disclosed to a person who is not a party to the proceeding without the express, writ-
ten consent of the person who submitted the information. There may be no discov-
ery in a proceeding on a petition other than the discovery required under this
paragraph.
Id.
115. Id. § 300aa-12(d)(1).
116. Id. § 300aa-12(d)(2).
117. Id. § 300aa-13(a)(1)(A).
118. Id. § 300aa-13(a)(1)(B). See also id. § 300aa-13(a)(2).
119. Id. § 300aa-13(b)(l)(A).
120. Id. § 300aa- I 2(d)(3). See also id. § 300aa-2 1(b). If the claims court fails to act within
one year of the petition date, the petitioner may withdraw the petition and file a civil action.
121. Id. § 300aa-12(e).
122. Budget Act History, supra note 83, at 693, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS at 2313-67. Awards for vaccine-related deaths are set at $250,000 regardless of
the date of death.
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cines administered after October 1, 1988, may include compensation
for actual unreimbursable 23 expenses incurred before and after the
judgment date, 124 actual and anticipated loss of earnings, 125 and ac-
tual and projected pain and suffering. 126  Compensation awards for
injuries sustained from vaccines administered prior to October 1,
1988,127 are similar in most respects, but do not allow awards for un-
reimbursable expenses incurred before the date of judgment.'2 8 The
Act specifically prohibits compensation in the form of punitive or ex-
emplary damages 129 or awards based on factors other than the health,
education, and welfare of the injured individual. 3 °
After the court renders a final decision, the petitioner must de-
cide whether to accept the court's decision or file a civil action' and,
in either case, must file an election in writing with the court no later
than ninety days after the entry of the court's judgment.13 2 Compen-
sation awards will not be paid until the petitioner makes an election to
accept the compensation and waives the right to file a civil action.
133
If the petitioner elects to accept the payment, compensation will be
paid from the date of judgment. 34 A similar written election must be
filed if the court does not award compensation and the petitioner
123. 42 U.S.C. § 300aa-15(g) (Supp. IV 1986). This section makes it clear that the pro-
gram is not primarily liable for vaccine injuries, and that awards will not cover expenses cov-
ered by other insurance or compensation programs.
124. Id. § 300aa-15(a)(1)(A). See also Budget Act History, supra note 83, at 693, reprinted
in 1987 U.S. CODE CONG. & ADMIN. NEWS at 2313-67, which states that awards will be made
in one lump sum payment based on the net present value of the award. The bill places a cap of
150 on the number of awards that may be paid in any year.
125. 42 U.S.C. § 300aa-15(a)(3) (Supp. IV 1986).
126. Id. § 300aa-15(a)(4). Compensation under this section is limited to $250,000.
127. Budget Act History, supra note 83, at 696, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS 2313-70.
128. 42 U.S.C. § 300aa-15(b) (Supp. IV 1986).
129. Id. § 300aa-15(d)(1).
130. Id. § 300aa-15(d)(2). See also Legislative History, supra note 3, at 20, reprinted in
1986 U.S. CODE CONG. & ADMIN. NEWS at 6361. The drafters recognized the special or
unusual health care and educational needs of vaccine-injured children and provided a broad
description of compensable care. Compensation will be awarded for needs ranging from spe-
cial nutrition to clothing for incontinence to physical protection. Id.
131. 42 U.S.C. § 300aa-21(a) (Supp. IV 1986).
132. Id. If the person does not file the required petition within the prescribed period, that
person will be deemed to have accepted the judgment of the court and will be barred from later
civil action. Id.
133. Id. § 300aa-15(f)(l).
134. Id. § 300aa-15(f)(2). Congressional appropriations will be used for payment of
awards for injuries incurred before the effective date of the Act. Payment of awards for inju-
ries incurred after the effective date will be provided through the Vaccine Injury Compensation
Trust Fund.
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wishes to proceed with a civil action. 135
The Act sets forth a table for use in determining a petitioner's
standing to file for compensation. 3 6 The table provides a list of vac-
cines covered by the Act and specific injuries attributable to such vac-
cines.137 Petitioners may only seek compensation under the program
135. Id. § 300aa-21(a)(2).
136. Id. § 300aa-14.
137. Id. For purposes of compensation, time periods in which the first symptoms or mani-
festations of illnesses occur after vaccine administration are specified in the table.
VACCINE INJURY TABLE
1. DTP; P; DTP/Polio Combination; or Any
Other Vaccine Containing Whole Cell
Pertussis Bacteria, Extracted or Partial Cell
Bacteria, or Specific Pertussis Antigen(s).
Illness, disability, injury, or condition Time period for first symptom or
covered: manifestation of onset or of significant
aggravation after vaccine
administration:
A. Anaphylaxis or anaphylactic shock ..... 24 hours
B. Encephalopathy (or encephalitis) ....... 3 days
C. Shock-collapse or hypotonic-
hyporesponsive collapse ............... 3 days
D. Residual seizure disorder in accordance
with subsection (c)(2) ................ 3 days
E. Any acute complication or sequela
(including death) of an illness,
disability, injury, or condition referred
to above which illness, disability,
injury, or condition arose within the
time period prescribed ................ Not Applicable
II. Measles, mumps, rubella, or any vaccine
containing any of the foregoing as a
component; DT; Td; or Tetanus toxoid.
A. Anaphylaxis or anaphylactic shock ..... 24 hours
B. Encephalopathy (or encephalitis) ....... 15 days (for mumps, rubella, measles,
or any vaccine containing any of the
foregoing as a component). 3 days
(for DT, Td, or tetanus toxoid).
C. Residual seizure disorder in accordance
with subsection (c)(2) ................ 15 days (for mumps, rubella, measles,
or any vaccine containing any of
the foregoing as a component). 3
days (for DT, Td, or tetanus
toxoid).
D. Any acute complication or sequela
(including death) of an illness,
disability, injury, or condition referred
to above which illness, disability,
injury, or condition arose within the
time period prescribed ................ Not Applicable
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if the injuries suffered are associated with vaccines listed in the ta-
ble.1 38 A related provision allows the Secretary of Health and Human
Services to promulgate changes in the table pertaining to the kinds of
injuries covered or the time period for onset of symptoms, 39 but the
power to add new vaccines to the table lies with Congress."
In addition to the standing restrictions of the Vaccine Injury Ta-
ble, there are also time limitations on petitions for compensation.
These limitations are based on the date of injury and its relation to the
effective date of the program. 41 Using these dates, the Act divides
potential petitioners into three groups:
1) [T]hose who were injured by a vaccine more than eight years
before enactment of the legislation; 2) those who were injured by a
vaccine that was administered before the enactment of the legisla-
tion but less than eight years ago; and 3) those who are injured by a
vaccine that is administered after the enactment of the
legislation. 142
Persons who suffered vaccine-related injuries more than eight years
before the effective date of the Act (group 1) are not eligible for com-
III. Polio Vaccines (other than Inactivated Polio
Vaccine).
A. Paralytic polio
-in a non-immunodeficient recipient ... 30 days
-in an immunodeficient recipient ...... 6 months
-in a vaccine-associated community
case .............................. Not Applicable
B. Any acute complication or sequela
(including death) of an illness,
disability, injury, or condition referred
to above which illness, disability,
injury, or condition arose within the
time period prescribed ................ Not Applicable
IV. Inactivated Polio Vaccine
A. Anaphylaxis or anaphylactic shock ..... 24 hours
B. Any acute complication or sequela
(including death) of an illness,
disability, injury, or condition referred
to above which illness, disability,
injury, or condition arose within the
time period prescribed ................ Not Applicable
Id. This section also includes interpretive aids for using the table. Id.
138. Id.
139. 42 U.S.C. § 300aa-14(c).
140. Id. § 300aa-14(e).
141. Id. § 300aa-16.
142. Legislative History, supra note 3, at 22, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6363-64.
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pensation under the Program' 43 and must seek compensation through
civil actions.
For injuries or death associated with vaccines administered less
than eight years before the effective date, petitions must be filed no
later than twenty-four months after the effective date. '44 Petitions for
injuries associated with vaccines administered after the effective date
must be filed no later than thirty-six months after the onset of the
injury's symptoms. 4 ' For deaths related to vaccines administered af-
ter the effective date of the Program, petitions must be filed no later
than twenty-four months after the date of death or forty-eight months
after the onset of symptoms from which death resulted.
46
A petitioner's right to file a civil suit after completing the com-
pensation proceedings is also protected under the Act. 14 7  State stat-
utes of limitations on civil actions for vaccine injuries will be stayed
during the pendency of the compensation proceedings. 48 Such a stay
begins on the date the petition is filed and ends on the date final judg-
ment is entered on the petition. '41
As noted above, petitioner retains the right to file a civil suit after
hearing the finding of the claims court. If the petitioner elects not to
accept compensation, the petitioner may file a civil action in a state
court. 5 ° State law will apply in most civil actions, but the Act will
supercede state law and protect manufacturers from some liability for
vaccines administered after October 1, 1988.'
Manufacturers may be relieved of liability for damages in actions
based on the unavoidable adverse side effects of a vaccine.'52 If the
manufacturer shows that it complied "in all material respects with all
requirements under the Federal Food, Drug, and Cosmetic Act,"
there is a presumption that all proper directions and warnings accom-
panied the vaccine. 53 This provision incorporates the principle of
comment k of Section 402A of the Restatement of Torts (Second) into
143. Id.
144. 42 U.S.C. § 300aa-16(a)(1) (Supp. IV 1986).
145. Id. § 300aa-16(a)(2).
146. Id. § 300aa-16(a)(3).
147. Id. § 300aa-16.
148. Id. § 300aa-16(c). See also § 300aa-16(b). The Act also makes provisions for revi-
sions of the Vaccine Injury Table and allows persons who become eligible for compensation
because of such revisions to file petitions within two years of the effective date of the revision.
Id.
149. Id. § 300aa-16(c).
150. Id. § 300aa-21(a).
151. Id. § 300aa-22(a).
152. Id. § 300aa-22(b)(1).
153. Id. § 300aa-22(b)(2).
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the Act. 154 The drafters intended to shield manufacturers from liabil-
ity for unavoidable adverse reactions.
155
To overcome this presumption, the plaintiff must show that the
manufacturer engaged in fraud or misrepresentation, intentional and
wrongful withholding of information, or other criminal or illegal ac-
tivity with respect to the safety of the vaccine.15 6 The plaintiff may
also overcome the presumption "by clear and convincing evidence
that the manufacturer failed to exercise due care notwithstanding its
compliance with [FDA regulations]." '' 7
The Act also protects manufacturers from liability based on fail-
ure to provide direct warnings to vaccine recipients. 15 8 If the plaintiff
alleges that the injury or death occurred solely as a result of the man-
ufacturer's failure to provide the vaccine recipient with direct warn-
ings of the potential dangers associated with vaccine administration,
the manufacturer may not be held liable.1 59 This provision is based
on the rationale that vaccine administrators should bear some of the
responsibility for providing such warnings. 160 It should be noted that
vaccine administrators also receive some measure of protection under
the Act in an amendment added "[to] remove any possibility for a
person to pursue a compensation claim while also pursuing a tort
claim against an administrator . . . [or] pursuing a tort claim after
accepting a compensation claim."'
16 1
154. Legislative History, supra note 3, at 25, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6366.
155. Id. at 26, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6367.
[E]ven if the defendant manufacturer may have made as safe a vaccine as anyone
reasonably could expect, a court or jury undoubtably will find it difficult to rule in
favor of the "innocent" manufacturer if the equally "innocent" child has to bear the
risk of loss with no other possibility of recompense.
Id.
156. 42 U.S.C. § 300aa-23(d)(2) (Supp. IV 1986).
157. Id. § 300aa-22(b)(2)(B).
158. Id. § 300aa-22(c). Civil actions for injuries incurred before October 1, 1988, will con-
tinue to be governed by appropriate state law. Id.
159. Id.
160. Legislative History, supra note 3, at 27, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6368.
If the manufacturer provides an adequate warning and adequate directions to an
intermediary such as a doctor, nurse or pharmacist who can be expected to know
about the product and its risks, and who is responsible for informing the ultimate
recipient of a vaccine . . . , the manufacturer should not be held liable for any failure
to warn or provide directions directly to a person . . . who is injured from the
vaccine.
Id.




Civil actions based on other theories are not prohibited by the
Act, and state law may not prohibit any actions allowed by the Act. 162
Any permissible civil action will be tried in three stages to determine
liability, general damages, and, if sought, punitive damages. 163 Find-
ings of the claims court or special master are not admissible in any
stage of a later civil action.1
The Act also provides for citizen's actions against the Secretary
for failure to perform acts or duties under the Act,1 65 and for judicial
review of regulations under the Act. 166 The Act also sets forth spe-
cific definitions to be used in the course of compensation
proceedings. 1
67
The Act's major influence on the practicing attorney arises from
the restrictions it places on when and how a civil action may be filed.
The attorney and client may not always be able to chart their own
course of action because the requirements of the Act must be fol-
lowed. A person who consults an attorney for the purpose of filing a
civil action against a manufacturer or administrator must be advised
of the Act's requirements and the limits on their actions.168
The use of the administrative proceeding will relieve the attorney
of some of the burdens of a civil action. Although the attorney must
collect and compile evidentiary material similar to that which would
be required in a civil action,169 he will be relieved of the burden of
pleading and proving fault on the part of the manufacturer or admin-
istrator. This should make the attorney's job much easier, because in
162. 42 U.S.C. § 300aa-22(e) (Supp. IV 1986).
163. Id. § 300aa-23(a)-(d). See also Legislative History, supra note 3, at 27, reprinted in
1986 U.S. CODE CONG. & ADMIN. NEWS at 6369. The issue of liability must be determined
before any consideration is given to the issue of damages. The drafters urge courts to use
diligence in their efforts to keep such deliberations free of irrelevant and prejudicial factors. If
the court finds the defendant is liable, it must then consider the issue of general damages.
Here, as in the consideration of punitive damages, the drafters intended to prevent the intro-
duction of evidence of the manufacturers' financial position. If the court finds evidence of
"'particularly reprehensible, conscious behavior" on the part of the manufacturer, punitive
damages may be considered and awarded. Id.
164. 42 U.S.C. § 300aa-23(e) (Supp. IV 1986). See also Legislative History, supra note 3, at
29, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6370. "Compensation standards,
evidence, and proceedings are sufficiently different from civil proceedings in tort that the find-
ings made in compensation are not likely to be based on the more rigorous requirements of a
tort proceeding and might confuse such civil actions." Id.
165. 42 U.S.C. § 300aa-31(a) (Supp. IV 1986).
166. Id. § 300aa-32. Review of administrative proceedings will be by a United States court
of appeals. Id.
167. Id. § 300aa-33.
168. Id. § 300aa- ll(a)(2)(A).
169. Id. § 300aa-I 1(c).
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the majority of cases, vaccine injuries are unavoidable and unforesee-
able. 171 In addition, use of the Compensation Program will, in many
cases, reduce the time an attorney must spend in pursuing a remedy
for the client since a judgment must be rendered within a year of the
filing of a petition. 171
If, after the completion of compensation proceedings, the client
elects not to accept the court's award and chooses to pursue a civil
action, the attorney is limited in the theories of liability that may be
used. Actions based on strict product liability and the "failure to
warn" premise used in Davis and Givens are now prohibited by the
Act. '72 The legislation's goal is not to make the practice of law easier
or more difficult, but to address the needs of the person suffering a
vaccine-related injury. The legislators intended to provide relief for
such a person by creating an "appealing alternative to the tort sys-
tem"' 173 that allows petitioners to be "compensated because they suf-
fered harm from the vaccine . . . not because they demonstrated
wrongdoing on the part of the manufacturer."'
174
The Act will also affect the attorney's potential fee. The Con-
gressional Budget Office (CBO) predicted that attorney and litigation
expenses will be lower'75 under the Compensation Program than in
civil actions. CBO's estimates will very likely be a factor in the deter-
mination of "reasonable attorneys' fees"' 1 76 to be included in compen-
sation awards.
The Act's impact on manufacturers is more difficult to predict
because persons suffering vaccine-related injuries are not compelled to
accept the judgment of the claims court. One of the early stumbling
blocks was the insistence by some of the Act's proponents that any
compensation program be the exclusive remedy. 77 These propo-
nents' 78 argued that manufacturers would not realize any relief from
170. Krugman, supra note 35.
171. Legislative History, supra note 3, at 17, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6358.
172. Id. at 27, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6368.
173. Id. at 26, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6367.
174. Id.
175. Budget Act History, supra note 83, at 695, reprinted in 1987 U.S. CODE CONG. &
ADMIN. NEWS at 2313-69. CBO estimates that attorney fees and other legal costs will be
about $50,000 per case.
176. 42 U.S.C. § 300aa-15(e) (Supp. IV 1986). The provisions of this section allow the
court to include attorney's fees and other costs in the amount of the award. Id.
177. Telephone interview with Elizabeth Goss, Legislative Assistant for Sen. Dale Bumpers
(Feb. 9, 1989).
178. Id. Proponents favoring administrative proceedings as an exclusive remedy include
the American Medical Association and manufacturers such as Lederle.
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the burdens of litigation if persons with vaccine-related injuries could
still seek relief in the courts. While this argument has some merit, it
is weakened by the tort reforms included in the Act. Although litiga-
tion is an option, the two most successful theories of liability are no
longer available. Although one cannot realistically presume that all
injured persons will accept the compensation offered, it seems reason-
able to assume that the awards granted will be acceptable to a sub-
stantial number of potential plaintiffs. The judiciary will be cognizant
of the availability of compensation under the Act, and while it is by
no means certain what effect this knowledge will have upon awards in
civil actions, it is at least conceivable that it may foster smaller
awards.
Because compensation is not available for persons injured more
than eight years before the effective date of the Act, manufacturers
will still face potential liability for these injuries. 179 However, time
and state statutes of limitations will act to reduce this burden.
The excise tax imposed on vaccines may at first glance appear to
place another burden on the manufacturers. However, manufacturers
increased the price of vaccines substantially in anticipation of the
taxes. 1 0 In reality, the monetary burden created by the excise tax will
be borne by state and local health departments in the form of in-
creased charges by manufacturers.
8 1
In addition to the monetary burdens, the Act will burden state
and local immunization programs in other ways. Under the Act, the
consent forms that must be signed by parents before a child may be
immunized are extremely long and complicated.' 82 Assuring that the
parents' consent is truly "informed" will require increased time and
effort on the part of public health officials. This will be especially true
in areas where adult illiteracy is a problem.
Two questions not answered by a careful reading of the Act and
its legislative history involve the Vaccine Injury Table and the vac-
cines covered by the compensation system. At present the table in-
cludes vaccines against only seven childhood diseases. 8 3 While the
179. Legislative History, supra note 3, at 22, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6363.
180. Telephone interview with Charles Beets, Director, Immunizations Program, Arkansas
Department of Health (Feb. 15, 1989).
181. Id.
182. Id. For example, the consent form used by the Arkansas Department of Health is
now nine pages in length instead of the original two pages.
183. See 42 U.S.C. § 300aa-14 (Supp. IV 1986) (measles, mumps, rubella, diphtheria, per-
tussis, polio, and tetanus).
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Act makes provisions for needed additions to the Table, such addi-
tions may be made only by congressional action.' 84 Although there is
some indication in the legislative history of the Act that certain addi-
tions would be favored,' there is no way of knowing when or if such
changes will be forthcoming.
It is also not certain if expansions of the table will include vac-
cines more commonly administered to adults. The swine flu vaccine
disaster 86 is a clear illustration that the risk of an adverse reaction is
not limited to the vaccines routinely administered to children.'8 7 At
present, it is not clear whether "adult" vaccines will be added to the
table, but the discovery of an AIDS vaccine would almost certainly
bring this question to the forefront. The ramifications of adding
"adult" vaccines to the table could be staggering because the number
of potential recipients would be great.
The National Childhood Vaccine Injury Compensation Act does
not answer all the questions and concerns associated with vaccine in-
juries, but it is a step in the right direction. The nation as a whole
benefits from its immunization programs, and a no fault compensa-
tion system appears to be the most logical way of assuring the contin-
ued success of such programs.
Victoria Bennett
184. 42 U.S.C. § 300aa-14(e).
185. Legislative History, supra note 3, at 20, reprinted in 1986 U.S. CODE CONG. & ADMIN.
NEWS at 6361. The drafters are particularly interested in the addition of Haemophilus in-
fluenzae and Hepatitis B vaccines to the Vaccine Injury Table. Id.
186. Smith, supra note 6, at 265. In 1976, in anticipation of a swine flu epidemic, the
Public Health Department sponsored a mass immunization program for that disease.
Although clinical trials of the vaccine revealed no adverse reactions, the administration of
several million doses resulted in a number of cases of Guillain-Barr6 syndrome. This syn-
drome causes a rapidly progressing muscular weakness which can lead to life-threatening re-
spiratory paralysis. Id.
187. Id.
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